63. Counseling to Prevent Unintended Pregnancy

63. Counseling to Prevent
Unintended Pregnancy
RECOMMENDATION
Periodic counseling about effective contraceptive methods is recom mended for all women and men at risk for unintended pregnancy (see
Clinical Intervention). Counseling should be based on information from a
careful sexual history and should take into account the individual preferences, abilities, and risks of each patient. Sexually active patients should
also receive information on measures to prevent sexually transmitted dis eases (see Chapter 62).
Burden of Suffering
Approximately two thirds of all American women are at risk for unintended pregnancy (i.e., they are sexually active but do not want to become
pregnant),1 and a substantial proportion of all pregnancies each year in
the U.S. are unintended.2 In a national survey of over 8,000 women ages
15–44,a 57% of all pregnancies were unintended, including those that were
unwanted (i.e., in women who did not want more children) and those that
were mistimed (i.e., in women who did not want children at that time).3,4
The proportion of pregnancies that are unintended is high in women of
all ages: 42% of all pregnancies in women ages 30–34 and 77% in women
ages 40–44.3 Births resulting from unintended and unwanted pregnancies
have gradually increased since 1982. Approximately 40% of live births to
women ages 15–44 were the result of unintended pregnancies, including
12% due to unwanted pregnancies.1
Unintended Teenage Pregnancies. An increasing number of teenagers are at
risk for unintended pregnancy. In a 1993 survey, 32% of 9th grade girls,
44% of 9th grade boys, and over two thirds of all high school seniors reported having had sexual intercourse; over half of seniors were sexually active within the previous 3 months.5 Factors associated with early sexual
activity include: lower socioeconomic status; use of tobacco, alcohol, or
other drugs; and single-parent households.6 Approximately 20% of sexua The 1988 National Survey of Family Growth (NSFG) is the source of the most widely cited statistics on unintended pregnancies and births. Data from the 1995 NSFG are scheduled to be released
in 1996.
739
740
Section II: Counseling
ally active teenage girls (age 15–19) become pregnant each year in the
U.S., and over 80% of teen pregnancies are unintended.6 Teenagers account for over 1 million pregnancies and over 500,000 births a year in the
U.S.7 Almost 40% of teenage births in 1992 were to mothers age 17 or
younger, including 12,000 births in girls under age 15.8 Although pregnancy rates among sexually active teens declined steadily from 1972 to
1986, pregnancy and birth rates have increased for the entire teen population, due to increasing teenage sexual activity and declining abortion
rates.6,7 The rates of teenage pregnancy and teenage birth (61 births/
1,000 women ages 15–19 in 1992) 8 remain substantially higher in the U.S.
than in most Western countries.6
Adverse Effects of Unintended Pregnancy. A 1995 Institute of Medicine (IOM)
report on unintended pregnancy summarized the consequences of unintended pregnancy for both the parents and the child.2 The most obvious
adverse consequence of unintended pregnancies is elective abortion.
Roughly half of all unintended pregnancies end in abortion, accounting
for most of the 1.5 million abortions performed annually in the U.S.9,10 Although abortion rates have declined modestly over the past 15 years in the
U.S.,10 they remain higher in the U.S. than in most Western countries.11
Separating the effects of unplanned births from other important social
and environmental factors (e.g., maternal health, education, and income)
is difficult. Adverse social and medical consequences are most consistently
observed for teenaged childbearing, most of which is attributable to unintended pregnancy. Teenage mothers are less likely to get or stay married,
less likely to complete high school or college, and more likely to require
public assistance and live in poverty. 2 Infants born to teenage mothers, especially mothers under age 15, are more likely to suffer from low birth
weight, neonatal mortality, and sudden infant death syndrome (SIDS),2
and they may be at greater risk of child abuse, neglect, and behavioral and
educational problems at later ages.12 Risk factors common in young mothers (poverty, single parenthood, poor nutrition, and inadequate prenatal
care) may be more important than young maternal age itself, however.13
From 1985 to 1990, the public costs of births to teenage mothers (Aid to
Families with Dependent Children, Medicaid, etc.) were estimated to be
over $120 billion.14
The adverse consequences of unintended pregnancy and childbirth
are not restricted to teenagers. Women who become pregnant unexpectedly forego the opportunity to receive preconception counseling to improve the health of the fetus.2 Pregnancies after age 40 are often
unintended and are associated with increased risks to both mother and infant. Women with unwanted pregnancies are less likely to receive adequate
prenatal care, more likely to smoke or drink, and more likely to have low
Chapter 63: Preventing Unintended Pregnancy
741
birth weight babies.2 Some studies have suggested that developmental
problems are more frequent among unwanted children,15 but other environmental factors are probably important; more than 40% of children resulting from unintended pregnancies in the U.S. are born into
single-parent families. 2
Efficacy of Risk Reduction
Complete sexual abstinence is the only certain form of contraception. Without contraception, an estimated 85% of heterosexual couples who engage in
regular intercourse will conceive within 1 year.16 Available methods to prevent conception vary considerably in their effectiveness, convenience, reversibility, side effects, and cost, and are reviewed in detail in a number of
up-to-date references.16,17
The effectiveness of contraceptive methods is usually expressed in two
ways: the failure rate under “perfect use” (annual pregnancy rates among
persons who use the method correctly on every occasion) and under “typical use” (average users in retrospective surveys or clinical trials).16,18 Because
many methods are not used consistently and correctly by the average couple,
failure rates with typical use are often considerably higher than with perfect
use. Nearly half of all unintended pregnancies occur in women who report
using some form of contraception,3 and inconsistent or incorrect use of contraception is the major cause of such contraception “failures.” User knowledge, motivation and ability, cooperation of their partner, the cost, comfort,
and ease of use of a particular method, and individual concerns about side
effects or safety are all important determinants of compliance with a chosen
method of contraception.
Contraceptive hormones include oral contraceptives (combined estrogen/progestin preparations and progestin-only pills), long-acting progestational agents that are injected or implanted, and postcoital
preparations.19 Combination oral contraceptives (OCs) are the most popular method of reversible contraception, used by an estimated 10 million
American women. The pill is generally taken daily for 21 days, followed by
either placebo or no pills for 7 days. The failure rate is about 3% per year
with typical use and as low as 0.1% per year when used correctly and consistently.16 Noncompliance remains the major cause of OC failure, especially
in unmarried women. Failure rates calculated from a 1988 survey were 7%;
rates were higher among women who were young, unmarried, or poor.18
Side effects of OCs, such as breakthrough bleeding, nausea, and breast
tenderness, decline over time and have been minimized in recent years by
lowering the dose of hormones. 16 Epidemiologic studies demonstrated an
association between early OCs and cardiovascular disease (myocardial infarction, stroke, and thromboembolic disorders).20 This effect was most
742
Section II: Counseling
pronounced in heavy smokers and older women, and has been attributed
to thrombotic effects of higher doses of hormones in early formulations.19,21 Any risks associated with current OCs seem to be minimal.16,22,23
In several studies conducted after 1985, OC use was associated with an increased risk of occlusive stroke (an extremely rare event in young
women),24–26 but effects on the risk of myocardial infarction have not
been consistent.27,28 For most women (with the possible exception of older
smokers), potential risks of OCs are lower than the risks of pregnancy and
childbirth.29 In one U.S. study of newer OCs, there were no cardiovascular
deaths in 55,000 patient-years of use.30 Patient satisfaction is generally
higher for OCs (94%) than most other methods.31
The net effect of OC use on cancer risk appears to be negligible and
may be favorable (see Chapter 64).32 The lifetime risk of breast cancer is
similar in OC users and nonusers, but some studies suggest a modest increase in early breast cancer among long-term users or those beginning
OC use at a young age.33,34 The absolute increase in risk is small, may be
due to factors other than OCs (e.g., delayed childbearing), and may not
apply to current formulations. A modest increase in cervical cancer has
also been reported, but the significance of this association is also controversial.19 In contrast, OC use is associated with a 40–50% reduction in the
risk of ovarian and endometrial cancer (see Chapter 64). Additional noncontraceptive benefits of OCs include lower incidence of menstrual disorders, benign breast disease, uterine fibroids, and clinical pelvic
inflammatory disease (PID). 17,35 Extended follow-up (12–20 years) of several large cohorts reported no effect of prolonged OC use on overall or
cause-specific mortality. 22,23
The progestin-only pill (“mini-pill”) is less effective than combination
OCs (failure rate 0.5–4%) and is more likely to cause irregular menses.16,36
It is a useful alternative for women who are breast-feeding or who have
contraindications to estrogen. Injectable progestins (depot-medroxyprogesterone acetate [DMPA], i.e., Depo-Provera) and subdermal progestin
implants (i.e., Norplant) provide long-term contraception without the
need for daily compliance. DMPA is administered as intramuscular injections given 4 times a year and has a failure rate of only 0.3%.16 Subdermal
implants can be inserted and removed as an office procedure and provide
effective contraception for up to 5 years. Cumulative 5-year pregnancy
rates in large case-series were 0.5–1.2%.37,38 Satisfaction with subdermal
implants seems high among selected groups39,40 but it is not as high as with
OCs. Common side effects with progestin-only contraceptives include irregular bleeding (up to 50–70%), headache, and weight gain; cases of
stroke and pseudotumor cerebri have been reported among users of Norplant, but no causal association has been established.41 Removal compli-
Chapter 63: Preventing Unintended Pregnancy
743
cations (e.g., broken or imbedded implants) occurred in 5% of patients in
1985–1993.42 Initial studies reported no significant increase in breast cancer,43 and a substantial reduction in endometrial cancer, 44 among women
using DMPA. DMPA causes modest adverse effects on serum lipids, but the
long-term effects on cardiovascular disease are not known for any of the
progestin-only contraceptives.
Postcoital administration of estrogen and progestin can reduce subsequent pregnancy if initiated within 72 hours after unprotected intercourse.45 The best-evaluated regimen consists of two doses of 100 µg ethinyl
estradiol and 1 mg levonorgestrel (i.e., two 50 µg combination OC pills),
given 12 hours apart. Based on reported failure rates (0.2–7.4%),46 it is estimated to reduce risk of pregnancy by 75%.16 Prominent side effects include
irregular bleeding, nausea (up to 50%), and vomiting.45 Alternate regimens
using danocrine (Danazol) have fewer side effects but have been less well
studied.47 In two recent trials in Great Britain, mifepristone (RU 486) was as
effective as, and better tolerated than, estrogen/progestin regimens for
postcoital contraception.47,48 RU 486 is under study in the U.S. but not yet
available.49 Surveys indicate that knowledge of and use of postcoital contraception remains low among patients and clinicians.16
Barrier contraceptive methods include the male and female condom
and female barriers used with spermicide. Barrier methods have fewer side
effects than hormonal contraception, but average effectiveness is more
variable due to inconsistent or incorrect use. When used reliably, latex
condoms have a 3% failure rate, compared to 12–16% among average
users.16,18 The female condom has failure rates comparable to other female barriers: 5% under perfect use and 20% under typical use.16 Cost
($2.50) and unfamiliar appearance may be obstacles to regular use.50
Latex condoms (and presumably female condoms) also provide protection against human immunodeficiency virus (HIV) and other sexually
transmitted diseases (STDs) (see Chapter 62). Condoms infrequently slip
or rupture, but most failure is due to inconsistent or improper use.
Other female barriers include the diaphragm, cervical cap, vaginal
sponge, and vaginal film. Diaphragms have a failure rate of about 6% when
used consistently, and 18–22% under average conditions.16,18 Among reliable users, failure rates appear higher (10% vs. 3%) in women having
more frequent intercourse (≥3 times per week).16 The cervical cap and
contraceptive vaginal sponge are as effective as the diaphragm in nulliparous women, but less effective in parous women (failure rates
20–36%).16 Both can be left in for longer periods than the diaphragm (24
hours). The only American manufacturer of sponges discontinued production in 1995, however.51 Spermicides (foams, creams, jellies) used
alone are estimated to have failure rates of 6% when used consistently and
744
Section II: Counseling
21–25% under typical usage conditions.16,18 Both barrier methods and
spermicides can reduce the risk of infection with gonorrhea and chlamydia, but effects on HIV transmission are uncertain (see Chapter 62).
Intrauterine devices (IUDs) can provide very effective contraception
(0.1–0.6% failure rate) for extended periods.16 Two IUDs are currently
available in the U.S.: a copper IUD (Paragard), approved for continued
use for up to 8 years, and a progesterone-releasing IUD (Progestasert),
which should be replaced annually; approval of a levonorgestrel IUD,
which can be left in place for 5 years, is pending in the U.S.16 Despite adverse publicity in the 1980s that led to the withdrawal of most IUDs from
the U.S. market, these newer IUDs have been used widely in other countries and have proven to be safe and reliable.52 In a study of nearly 23,000
women, the risk of PID was increased only in the first 20 days following
IUD insertion, but thereafter remained low (1.6 cases/1,000 years of
use);53 risk was not increased among monogamous women using IUDs. Between 2% and 10% of women will experience expulsion of their IUD in
the first year, and up to 15% may require removal due to pain or bleeding.
For many women, especially those at low risk of STDs, IUDs offer excellent
alternatives to OCs and other methods.
Coitus interruptus (withdrawal) and periodic abstinence may be more
acceptable alternatives for persons with religious objections to artificial
contraception54 and others who are unwilling or unable to use other
methods. It is often difficult to perform these methods correctly. Abstinence during fertile periods can be based on date of last menstrual period
(calendar or “rhythm” method) or changes in temperature or cervical
mucus (ovulation method). The ovulation method is more effective than
the calendar method (1–3% vs. 9% failure rate under perfect use)16,55 but
requires abstinence for about 17 days of each cycle.17,56,57 Coitus interruptus can fail if withdrawal is not timed properly or if preejaculatory fluid
contains sperm. Due to these difficulties, failure rates of withdrawal and
periodic abstinence are 18–20% annually in actual practice.16,18 Effectiveness may be improved by combining these methods with other contraception during the fertile period of the menstrual cycle.
Sterilization is the most common method of contraception in the
U.S.62 and has no proven long-term risks.16 It differs from other methods
in that it is intended to provide permanent contraception. The average
failure rate is 0.1–0.2% for male sterilization (vasectomy) and 0.4% for female sterilization (tubal ligation).16 Between 1% and 2% of vasectomies
are accompanied by transient side effects (hematoma, infection, or epididymitis).16 The complication rate from tubal ligation depends on the
type of procedure (e.g., mini-laparotomy, laparoscopy, colpotomy) but is
generally less than 1%.16 Within 2 years of the procedure, up to 3% of
American women reported regret over sterilization.58,59 Fertility can be restored in up to 50% of men after reversal of vasectomy, and up to 70% of
Chapter 63: Preventing Unintended Pregnancy
745
women after reversal of tubal ligation.16 Sterilization does not protect
against sexually transmitted infections, but tubal ligation is associated with
lower risk of PID and ovarian cancer.60,61
Effectiveness of Counseling
Many adolescents and adults could potentially benefit from counseling
about how to prevent unintended pregnancy. In a 1990 survey, 12% of sexually active women ages 15–44, and 22% of sexually active teens, reported
not practicing any form of contraception.62 Contraception use at first premarital intercourse remains lower than at any other stage in life: 29% of all
teens and more than half of women under age 17 report using no contraception at first intercourse.63 Many more persons use contraception but
fail to use it consistently or correctly. Nearly half of all unintended pregnancies occur in women using a contraceptive method. Among teenagers,
the most common reasons given by teenagers for not using contraception
at last intercourse were “Didn’t expect to have sex” and “Just didn’t think
pregnancy would occur.” 64 In one study of college students fitted for a diaphragm, only 57% reported using it with each coitus.65
Information on the effectiveness of counseling by primary care clinicians in altering sexual practices or improving the use of contraception remains limited, however. What evidence does exist comes primarily from
studies of interventions delivered in other settings (classrooms, school clinics, family planning clinics) or targeted to AIDS-related behaviors rather
than unintended pregnancy. The 1995 IOM report identified 23 pregnancy prevention programs that had been adequately evaluated, most of
which targeted high-risk adolescents.2 These programs employed a variety
of interventions: community- and school-based education about sexuality,
life skills, and contraception; individual counseling through school or hospital clinics; and provision of contraceptive services. Most evaluations were
based on change in self-reported sexual activity and contraceptive use
rather than actual rates of unintended pregnancy. There were several
major conclusions of the IOM review: only 13 of 23 programs were even
somewhat effective in changing behavior, and magnitude of effect was
often small; evidence of the effectiveness of abstinence-only programs was
inconclusive; education programs that provided information on both abstinence and contraceptive use had generally favorable effects, without
promoting early sexual activity or frequency of intercourse; and only a few
programs included measures to ensure access to contraception.
One of the most effective programs combined a school curriculum
with free contraceptive services through a school-linked clinic.66 Another
community-based program that included contraceptive services demonstrated early success in preventing adolescent pregnancy,67 but not in later
years after contraceptive services were dropped.68 Evaluations of other
746
Section II: Counseling
school-based clinics suggest no clear effect on teenage birth rates,64,69,70
but most pregnancies occurred before students had used the clinic or discussed birth control. 64
Kirby et al. 71 reviewed the effects of 23 school programs providing sex
and HIV education (including some reviewed in the IOM report). They
noted isolated positive effects of some programs on use of contraception
at first intercourse, but less effect on contraception use among sexually experienced teens. As in the IOM report, they found no evidence that education about sexuality or instruction about contraception led to earlier or
more frequent sexual activity among teenagers. All effective programs
went well beyond simply providing factual information about contraception and sexuality; most sought to reinforce specific norms about sexual
behavior and to develop skills to help teens resist sexual pressures.
A variety of HIV prevention programs have employed individual or
group counseling in a clinic setting (see Chapter 62). A number of these
demonstrated an increase in condom use after counseling men, but interventions emphasized STD prevention rather than contraception. A randomized trial of reproductive health counseling of young men age 15–18
did not increase overall use of contraception or use of condoms.72
Access to family planning clinics appears to help prevent unintended
adolescent pregnancy. Teenagers who attend family planning clinics were
more likely to use oral contraceptives and less likely to engage in unprotected sexual intercourse;73 adolescents living in communities with subsidized family planning services were less likely to become pregnant in one
analysis.74 Clinic attenders are self-selected, however, and many of the effects of counseling are short-lived. In one study, less than one half of all
adolescents attending a family planning clinic were compliant with contraception after 1 year.75 Attempts to improve compliance through family
counseling, telephone follow-up, or contingency planning have met with
limited success.76,77
There are obvious limitations in generalizing from such programs to
routine office counseling by clinicians. Furthermore, little is known about
interventions to improve contraception in nonadolescent women and
men.2 At the same time, the potential to improve counseling practices in
the primary care setting is apparent. A minority of primary care
providers—from 18% of pediatricians to 53% of nurse practitioners—routinely ask their female patients about family planning needs.78 Surveys document that many adolescents and adults are misinformed about the risks
of unintended pregnancy, the benefits and risks of particular contraceptive methods, and the proper use of contraception.2 Misperceptions about
risks of contraception (especially OCs and IUDs) are important reasons
why women delay seeking contraceptive services, use contraceptives inconsistently, or prematurely discontinue their use.
Chapter 63: Preventing Unintended Pregnancy
747
The effectiveness of counseling depends on the age, maturity, sex, and experience of the patient, as well as on the level of training and counseling skills
of the provider.79 Selection of an appropriate method of birth control must
take into consideration the personal preferences, religious beliefs, and abilities of the patient, and the nature of their relationship with their partner(s).
As documented in the IOM report, physician training in family planning is
highly variable and often limited.2 Many clinicians are reluctant to prescribe
contraceptives for adolescents without parental consent,80 although most
states explicitly or implicitly permit minors to consent b to contraceptive services without parental approval.81 Informing parents may discourage adolescents from seeking needed assistance and conflict with the duty to protect the
well-being of the patient and the confidentiality of the doctor-patient relationship.82 Concern that a physician will inform parents is commonly cited
by adolescents as a reason for choosing family planning clinics over private
physicians to obtain contraception.83 Of the estimated 5 million teenaged
women at risk for unintended pregnancy in the U.S., however, only 1.2 million receive services at publicly funded family planning clinics.84
Recommendations of Other Groups
Numerous organizations recommend counseling sexually active adolescents and adults about unintended pregnancy. The American Academy of
Family Physicians,85 the AMA Guidelines for Adolescent Preventive Services (GAPS),86 the American Academy of Pediatrics (AAP)87, the American College of Obstetricians and Gynecologists (ACOG),88 the Society for
Adolescent Medicine,89 the Canadian Task Force on the Periodic Health
Examination,90 and Bright Futures94 each recommends that clinicians
counsel all adolescents about preventing unintended pregnancy (including the role of abstinence) and provide effective contraception for all sexually active patients. These groups also encourage physicians to protect the
confidentiality of the doctor-adolescent relationship within the confines of
local legal requirements regarding parental consent. Healthy People 2000,
a U.S. Public Health Service report of national health objectives, endorses
efforts to increase sexual abstinence among adolescents and increase the
proportion of primary care providers offering age-appropriate family planing counseling.91 Updated family planning information from the World
Health Organization was released in 1995.92
Discussion
Unintended pregnancy remains a critical problem in the U.S. Although
the consequences of unintended pregnancy are most pronounced in
b Some states permit minor consent on the basis of age (age 14 or 16) or if referred by doctor, family planning agency or school.
748
Section II: Counseling
young, unmarried women, the problem affects women and men throughout the reproductive period of their lives. Multiple factors are involved in
unintended pregnancy, including personal and societal attitudes toward
sex, contraception, and pregnancy. Postponing early sexual activity among
teens and increasing the consistent use of effective contraception continue
to be elusive goals for parents, clinicians, and educators alike. Nonetheless,
a variety of evidence indicates that a combination of patient education and
access to effective contraception can reduce unintended pregnancy. Although their ability to influence patient sexual behavior may be limited,
clinicians can offer information about contraceptive options and prescribe
effective and appropriate contraception. The public health benefits of better contraceptive practices would be enormous: reducing the proportion
of women not using contraception by half could prevent as many as one
third of all unintended pregnancies and 500,000 abortions per year.93
There is no ideal contraceptive method for all patients. The choice of
an appropriate method must consider each patient’s motivation and ability to use a particular method, their individual preferences (and partner’s
preferences), cost and safety factors, and their relationship with their sexual partner(s). Women bear the largest burden from unintended pregnancy, and methods under female control (hormonal contraception,
IUDs, and female barriers) appear to be used more regularly than those
requiring male cooperation (condoms, coitus interruptus, periodic abstinence). On the other hand, female methods (with the possible exception
of the female condom) do not offer reliable protection against transmission of HIV or other STDs, which are important threats to many individuals. The importance of measures to reduce the risk of STDs (abstinence,
maintaining monogamous relationships, avoiding sex with high-risk persons, and using condoms consistently) need to be emphasized along with
the importance of effective contraception. Clinicians need to remain alert
to factors that may contribute to noncompliance (anxiety, cost, discomfort, embarrassment, etc.).
The effectiveness of counseling depends in part on the clinician’s sensitivity to the personal concerns and privacy of the patient. These issues are
especially important when addressing issues of sexuality with adolescents,
who may have conflicted feelings about sexuality or childbearing, limited
information about fertility and contraception, and unrealistic perceptions
of the risks of unprotected sex. Clinicians can encourage abstinence as the
safest choice, provide support for individuals choosing to postpone sexual
activity, and prescribe effective contraceptive methods for young persons
who continue to be at risk. The low rate of contraception at first intercourse indicates that discussion of sexuality and contraception should
begin before adolescents become sexually active.
Chapter 63: Preventing Unintended Pregnancy
749
CLINICAL INTERVENTION
Periodic counseling about effective contraceptive methods is recom mended for all women and men at risk for unintended pregnancy (“B” recommendation). Counseling should be based on information from a
careful history that includes direct questions about sexual activity, current
and past use of contraception, level of concern about pregnancy, and past
history of unintended pregnancies. Counseling should take into account
the individual preferences, concerns, abilities, and risks of each patient
and his or her partner, including risk of STDs (see Chapter 62). Counseling should include a discussion of the risk associated with the patient’s current contraceptive practice and, when indicated, available alternatives for
more effective contraception. Clinicians should inform adolescent patients that abstinence is the most effective way to prevent unintended pregnancy and STDs, although the effectiveness of abstinence counseling has
not been established.
Clear instructions should be provided for the proper use of recom mended contraceptive techniques. Hormonal contraceptives, barrier
methods used with spermicides, and IUDs should be recommended as the
most effective reversible means of preventing pregnancy in sexually active
persons. Sexual abstinence, the maintenance of a mutually faithful monogamous sexual relationship, and consistent use of condoms should be emphasized as important measures to reduce the risk of STDs (see Chapter
62). Clinicians should monitor satisfaction and compliance of patients with
any chosen form of contraception.
Empathy, confidentiality, and a nonjudgmental, supportive attitude are
especially important when discussing issues of sexuality with adolescents.
Clinicians should involve young pubertal patients (and their parents,
where appropriate) in early, open discussion of sexual development and
effective methods to prevent unintended pregnancy and STDs. Clinicians
should explore attitudes and expectations of adolescents and other patients who are not currently involved in a sexual relationship to anticipate
future need for contraception, and inform them how to obtain information and contraception if they plan to begin engaging in sexual intercourse.
Preferably, adolescents should be examined without their parent(s) present. Clinicians providing birth control for minors should take into consideration both the confidentiality of the doctor-patient relationship as
well as local legal restrictions when deciding whether to notify parents before prescribing contraception. The optimal frequency of counseling to
prevent unintended pregnancy is unknown and is left to clinical discretion.
The draft update of this chapter was prepared for the U.S. Preventive Services Task
Force by David Atkins, MD, MPH, with contributions from materials prepared by
750
Section II: Counseling
William Feldman, MD, FRCPC, Anne Martell, MA, CMC, and Jennifer L. Dingle, MBA,
for the Canadian Task Force on the Periodic Health Examination.
REFERENCES
1. Forrest JD, Singh S. The sexual and reproductive behavior of American women, 1982–1988. Fam Plann
Perspect 1990;22:206–214.
2. Committee on Unintended Pregnancy, Institute of Medicine. The best intentions: unintended pregnancy and the well-being of children and families. Brown SS, Eisenberg L, eds. Washington DC: National Academy Press, 1995.
3. Forrest JD. Epidemiology of unintended pregnancy and contraceptive use. Am J Obstet Gynecol 1994;
170(Suppl 2):1485–1489.
4. Piccinino LJ. Unintended pregnancy and childbearing. In: Wilcox LS, Marks JS, eds. From data to action: CDC’s public health surveillance for women, infants, and children. Washington, DC: U.S. Department of Health and Human Services, 1994:73–82.
5. Centers for Disease Control and Prevention. Youth Risk Behavior Surveillance—United States, 1993.
MMWR 1995; 44(SS-1):1–56.
6. Alan Guttmacher Institute. Sex and America’s teenagers. New York: Alan Guttmacher Institute, 1994.
7. Ventura SJ, Taffel SM, Mosher WD, et al. Trends in pregnancies and pregnancy rates: estimates for the
United States, 1980–92. Monthly vital statistics report; vol 43 no 11 (suppl). Hyattsville, MD: National
Center for Health Statistics, 1995.
8. Ventura SJ, Martin JA, Taffel SM, et al. Advance report of final natality statistics, 1992. Monthly vital statistics report; vol 43 no 5 (suppl). Hyattsville, MD: National Center for Health Statistics, 1994.
9. Koonin LM, Smith JC, Ramick M. Abortion surveillance—United States, 1991. In: CDC Surveillance
Summaries, May 1995. MMWR 1995;44(SS-2):23–53.
10. Henshaw SK, Van Vort J. Abortion services in the United States, 1991 and 1992. Fam Plann Perspect
1994;26: 100–106, 112.
11. Henshaw SK. Induced abortion: a world review, 1990. Fam Plann Perspect 1990;22:76–89.
12. Furstenberg FF Jr, Brooks-Gunn J, Morgan SP. Adolescent mothers and their children in later life. Fam
Plann Perspect 1987;19:142–51.
13. National Institute of Child Health and Human Development. Summary of a conference. Outcomes of
early childbearing: an appraisal of recent evidence. Bethesda: National Institute of Child Health and
Development, May 1992.
14. Center for Population Options. Teenage pregnancy and too-early childbearing: public costs, personal
consequences. 6th ed. Washington, DC: Center for Population Options, 1992.
15. Myhrman A. Family relation and social competence of children unwanted at birth: a follow-up study at
the age of 16. Acta Psychiatr Scand 1988;77:181–187.
16. Hatcher RA, Guest F, Stewart F, et al. Contraceptive technology. 16th rev ed. New York: Irvington, 1994.
17. Speroff L, Darney P. A clinical guide for contraception. Baltimore: Williams & Wilkins, 1992.
18. Jones EF, Forrest JD. Contraceptive failure rates based on the 1988 NSFG. Fam Plann Perspect
1992;24:12–19.
19. Baird DT, Glasier AF. Hormonal contraception. N Engl J Med 1993;328:1543–1549.
20. Stampfer MJ, Willett WC, Colditz GA, et al. Past use of oral contraceptives and cardiovascular disease:
a meta-analysis in the context of the Nurses’ Health Study. Am J Obstet Gynecol 1990;163:285–291.
21. DaVanzo J, Parnell AM, Foege WH. Health consequences of contraceptive use and reproductive patterns. Summary of a report from the U.S. National Research Council. JAMA 1991;265:2692–2696.
22. Vessey MP, Villard-Mackintosh I, McPherson K, et al. Mortality among oral contraceptive users: 20 years
follow up of women in a cohort study. BMJ 1989;299:1487–1491.
23. Colditz GA for the Nurses’ Health Study Research Group. Oral contraceptive use and mortality during
12 years of follow-up: the Nurses’ Health Study. Ann Intern Med 1994;120:821–826.
24. Thorogood M, Mann J, Vessey M. Fatal stroke and use of oral contraceptives: findings from a case-control study. Am J Epidemiol 1992;136:35–45.
25. Hannaford PC, Croft PR, Kay CR. Oral contraception and stroke. Evidence from the Royal College of
General Practitioners’ oral contraception study. Stroke 1994;25:935–942.
26. Lidegard O. Oral contraception and risk of cerebral thromboembolic attack: results of a case-control
study. BMJ 1993;306:956–963.
Chapter 63: Preventing Unintended Pregnancy
751
27. Rosenberg L, Palmer JR, Lesko S, et al. Oral contraceptive use and the risk of myocardial infarction.
Am J Epidemiol 1990;131:1009–1016.
28. Thorogood M, Mann J, Murphy M, et al. Is oral contraceptive use still associated with an increased risk
of fatal myocardial infarction? Report of a case-control study. Br J Obstet Gynaecol 1991;98:1245–1253.
29. Kost K, Forrest JD, Harlap S. Comparing the health risks and benefits of contraceptive choices. Fam
Plann Perspect 1991;23:54–61.
30. Porter JB, Hershel J, Walker AM. Mortality among oral contraceptive users. Obstet Gynecol
1987;70:29–32.
31. Forrest JD, Fordyce RR. Women’s contraceptive attitudes and use in 1992. Fam Plann Perspect
1993;25:175–179.
32. Schlesselman JJ. Net effect of oral contraceptive use on the risk of cancer in women in the United States.
Obstet Gynecol 1995;85:793–801.
33. Malone KE, Daling JR, Weiss NS. Oral contraceptives in relation to breast cancer. Epidemiol Rev
1993;15:80–97.
34. Romieu I, Berlin JA, Colditz G. Oral contraceptives and breast cancer: review and meta-analysis. Cancer 1990;66: 2253–2263.
35. Harlap S, Kost K, Forrest JD, eds. Preventing pregnancy, protecting health: a new look at birth control
choices in the United States. New York: Alan Guttmacher Institute, 1991.
36. Chi I. The safety and efficacy issues of progestin-only oral contraceptives—an epidemiologic perspective. Contraception 1993;47:1–21.
37. Xiao BL, Gu SJ, Wang SL, et al. Norplant and the levonorgestrel IUD in Chinese family planning programs. Ann Med 1993;25:161–163.
38. Su-Juan G, Ming Kun D, Ling-De Z, et al. A 5-year evaluation of NORPLANT contraceptive implants in
China. Obstet Gynecol 1994;83:673–678.
39. Polaneczky M, Slap G, Forke C, et al. The use of levonorgestrel implants (Norplant) for contraception
in adolescent mothers. N Engl J Med 1994;331:1201–1206.
40. Berenson AB, Wiemann CM. Patient satisfaction and side effects with levonorgestrel implant (Norplant)
use in adolescents 18 years or younger. Pediatrics 1993;92:257–260.
41. Wysowski DK, Green L. Serious adverse events in Norplant users reported to the Food and Drug Administration’s MedWatch spontaneous reporting system. Obstet Gynecol 1995;85:538–542.
42. Dunson TR, Amatya RN, Krueger SL. Complications and risk factors associated with the removal of Norplant implants. Obstet Gynecol 1995;85:543–548.
43. World Health Organization. Depot-medroxyprogesterone acetate (DMPA) and cancer: memorandum
from a WHO meeting. Bull WHO 1993;71:669–676.
44. Kaunitz AM. Long-acting injectable contraception with DMPA. Am J Obstet Gynecol
1994;170:1543–1549.
45. Trussell J, Stewart F, Hatcher RA. Emergency contraceptive pills: a simple proposal to reduce unintended pregnancies. Fam Plann Perspect 1992;24:269–273.
46. Fasoli M, Parazzini F, Cecchetti G, et al. Post-coital contraception: an overview of published studies. Contraception 1989;39:459–468. [Erratum, Contraception 1989;39:699].
47. Webb A, Russell J, Elstein M. Comparison of Yuzpe regimen, danazol, and mifepristone (RU 486) in
postcoital contraception. BMJ 1992;305:927–931.
48. Glasier A, Thong KJ, Dewar M, et al. Mifepristone (RU 486) compared with high-dose estrogen and
progestogen for emergency postcoital contraception. N Engl J Med 1992;327:1041–1044.
49. The contraception report. Warren Township, NJ: Emron, Inc., 1994. Vol V, no. 3, p. 14.
50. Farr G, Gabelnick H, Sturgen K, et al. Contraceptive efficacy and acceptability of the female condom.
Am J Public Health 1994;84:1960–1964.
51. Choice of contraceptives. Med Lett Drugs Ther 1995;37:9–12.
52. Diagnostic and therapeutic technology assessment. Intrauterine devices. JAMA 1989;261:2127–2130.
53. Farley TMM, Rosenberg MJ, Rowe PJ, et al. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992;339:785–788.
54. Notzer N, Levran D, Mashiach S, et al. Effect of religiosity on sex attitudes, experience and contraception among university students. J Sex Marital Ther 1984;10:57–62.
55. Trussell J, Grummer-Strawn L. Contraceptive failure of the ovulation method of periodic abstinence.
Fam Plann Perspect 1990;22:65–75.
56. World Health Organization. A prospective multicenter trial of the ovulation method of natural family
planning. IV. The outcome of pregnancy. Fertil Steril 1984;41:593–598.
752
Section II: Counseling
57. Klaus H, Goebel JM, Muraski B, et al. Use-effectiveness and client satisfaction in six centers teaching the
Billings ovulation method. Contraception 1979;19:613–629.
58. Grubb G, Refoser H, Layde PM, et al. Regret after decision to have a tubal sterilization. Fertil Steril
1985;44: 248–253.
59. Wilcox LS, Chu SY, Peterson HB, et al. Characteristics of women who considered or obtained tubal reanastomosis: results from a prospective study of tubal sterilization. Obstet Gynecol 1990;75:661–665.
60. Phillips AJ, D’Ablaing G. Acute salpingitis subsequent to tubal ligation. Obstet Gynecol
1986;67:55S–58S.
61. Hankinson SE, Hunter DJ, Colditz GA, et al. Tubal ligation, hysterectomy, and risk of ovarian cancer:
a prospective study. JAMA 1993;270:2813–2818.
62. Peterson LS. Contraceptive use in the United States, 1982–90. Advance data from vital and health statistics; no. 260. Hyattsville, MD: National Center for Health Statistics, 1995.
63. Mosher WD, McNally JW. Contraceptive use at first pre-marital intercourse: United States, 1965–1988.
Fam Plann Perspect 1991;23:108–116.
64. Kirby D, Waszak C, Ziegler J. Six school-based clinics: their reproductive health services and impact on
sexual behavior. Fam Plann Perspect 1991;23:6–16.
65. Loucks A. A comparison of satisfaction with types of diaphragms among women in a college population. J Obstet Gynecol Neonatal Nurs 1989;18:194–200.
66. Zabin LS, Hirsch MB, Smith EA, et al. Evaluation of a pregnancy prevention program for urban
teenagers. Fam Plann Perspect 1986;18:119–26.
67. Vincent ML, Clearie AR, Schluchter MD. Reducing adolescent pregnancy through school and community-based education. JAMA 1987;257:3382–3386.
68. Koo HP, Dunteman GH, George G, et al. Reducing adolescent pregnancy through a school- and community-based intervention: Denmark, South Carolina, revisited. Fam Plann Perspect 1994;26:206–211,
217.
69. Edwards L, Steinman M, Arnold K, et al. Adolescent pregnancy services in high school clinics. Fam Plann
Perspect 1980;12:6–14.
70. Kirby D, Resnick MD, Downes B, et al. The effects of school based health clinics in St. Paul on schoolwide birthrates. Fam Plann Perspect 1993;25:12–16.
71. Kirby D, Short L, Collins J, et al. School-based programs to reduce sexual risk behaviors: a review of effectiveness. Public Health Rep 1994;109:339–360.
72. Danielson R, Marcy S, Plunkett A, et al. Reproductive health counseling for young men: what does it
do? Fam Plann Perspect 1990;22:115–121.
73. Forrest JD, Hermalin A, Henshaw SK. The impact of family planning clinic programs on adolescent
pregnancy. Fam Plann Perspect 1981;13:109–116.
74. Moore KA, Caldwell SB. The effect of government policies on out-of-wedlock sex and pregnancy. Fam
Plann Perspect 1977;9:164–169.
75. Emans SJ, Grace E, Woods E, et al. Adolescents’ compliance with the use of oral contraceptives. JAMA
1987;257: 3377–3381.
76. Herceg-Baron R, Furstenberg FF Jr, Shea J, et al. Supporting teenagers’ use of contraceptives: a comparison of clinic services. Fam Plann Perspect 1986;18:61–66.
77. Namerow PB, Weatherby N, Williams-Kaye J. The effectiveness of contingency-planning counseling.
Fam Plann Perspect 1989;21:115–119.
78. National Center for Health Statistics. Healthy People 2000 review, 1994. Hyattsville, MD: U.S. Public
Health Service, 1995. (Publication no. PHS-95-1256-1).
79. Nathanson CA, Becker MH. The influence of client-provider relationships on teenage women’s subsequent use of contraception. Am J Public Health 1985;75:33–38.
80. Orr M. Private physicians and the provision of contraceptives to adolescents. Fam Plann Perspect
1984;16:83–86.
81. Donovan P. Our daughter’s decisions: the conflict in state law on abortion and other issues. New York:
Alan Guttmacher Institute, 1992.
82. Committee on Education in Family Life, American College of Obstetricians and Gynecologists. The
management of sexual crises in the minor female. Washington, DC: American College of Obstetricians
and Gynecologists, 1982.
83. Chamie M, Eisman S, Forrest JD, et al. Factors affecting adolescents’ use of family planning clinics. Fam
Plann Perspect 1982;14:126–139.
Chapter 63: Preventing Unintended Pregnancy
753
84. Smith JC, Franchino B, Henneberry JF. Surveillance of family planning services at Title X clinics and
characteristics of women receiving these services, 1991. In: CDC surveillance summaries, May 5, 1995.
MMWR 1995;44(SS-2):1–21.
85. American Academy of Family Physicians. Age charts for periodic health examination. Kansas City, MO:
American Academy of Family Physicians, 1994. (Reprint no. 510.)
86. American Medical Association. Guidelines for adolescent preventive services (GAPS): recommendations and rationale. Chicago: American Medical Association, 1994.
87. American Academy of Pediatrics. Contraception and adolescents. Pediatrics 1990;86:134–138.
88. American College of Obstetricians and Gynecologists. The adolescent obstetric-gynecologic patient.
Technical Bulletin no. 145. Washington, DC: American College of Obstetricians and Gynecologists,
1990.
89. Society for Adolescent Medicine. Position papers on reproductive health care for adolescents. J Adolesc Health Care 1983;4:208–210.
90. Canadian Task Force on the Periodic Health Examination. Canadian guide to clinical preventive health
care. Ottawa: Canada Communication Group, 1994:540–547.
91. U.S. Department of Health and Human Services. Healthy People 2000: national health promotion and
disease prevention objectives. Washington, DC: Public Health Service, 1991:185–205. (Publication no.
PHS-91-50212.)
92. World Health Organization Special Programme of Research, Development and Research Training in
Human Reproduction. Annual technical report—1994. Geneva: WHO, 1995. (WHO/HRP/ATR/
94/95.)
93. Mosher W. Fertility and family planning in the United States: insights from the National Survey of Family Growth. Fam Plann Perspect 1988;20:207–217.
94. Green M, ed. Bright Futures: guidelines for health supervision of infants, children, and adolescents. Arlington VA: National Center for Education in Maternal and Child Health, 1994.